Key Highlights

  • Revenue was USD 396.34 million against an estimate of USD 384.95 million.
  • EPS was USD 0.07 against an estimate of a USD 3.97 loss.
  • Adjusted EBITDA was USD 21 million, bringing the year-to-date total to USD 101 million.
  • The low end of full-year adjusted EBITDA guidance was raised to USD 90 million.

P3 Health Partners (NASDAQ:PIII) reported third quarter 2026 Revenue of USD 396.34 million, against an estimate of USD 384.95 million and USD 345.25 million in the third quarter of 2025. EPS was USD 0.07, compared with an estimate of a USD 3.97 loss. Basic Earnings Per Share attributable to Class A common stockholders were USD 0.13, against a loss of USD 9.67.

Net income attributable to Class A common stockholders was USD 451 thousand, compared with a net loss of USD 31.59 million a year earlier. Income before income taxes was USD 30.80 million, against a loss of USD 69.45 million.

Adjusted EBITDA and Guidance

Chief executive officer Aric Coffman said the third quarter results included USD 21 million of adjusted EBITDA, bringing year-to-date adjusted EBITDA to USD 101 million. Management said it is raising the low end of its full-year adjusted EBITDA guidance to USD 90 million and increasing the midpoint to USD 100 million.

Management said year-to-date Medicare Advantage medical expense is 0.7% below full-year 2025 medical expense on a normalized basis, and described this as bending the medical cost curve through the first three quarters. It noted that peers in the sector were reporting medical cost trend of 7% or more.

Nine-Month Results and Other Items

For the nine months ended September 30, 2026, total revenue was USD 1.17 billion, compared with USD 1.07 billion. The net loss attributable to Class A common stockholders for the nine months was USD 452 thousand, compared with USD 72.43 million, and the basic loss per share was USD 0.13, against USD 22.18.

The company recognized a gain of USD 2.9 million from an increase in the Fair Value of its purchased put option, and a gain of USD 4.7 million related to its liability-classified stock warrants, compared with a loss of USD 2.5 million in the prior-year quarter.

Debt Exchange and Going Concern

The filing describes a Debt Exchange Agreement entered into on April 27, 2026 with affiliates of Chicago Pacific Founders, the company's largest stockholder and debtholder. It also describes the development of a revenue estimation model that uses historical payment experience and membership data to estimate ultimate consideration for completed utilization periods under an agreement for which revenue was previously recognized only when cash was received.

The filing states that substantial doubt exists about the company's ability to continue as a Going Concern for one year after the date the financial statements are issued.

P3 Health Partners Q3 2026 Earnings: Key Takeaways

P3 Health Partners reported third quarter 2026 revenue of USD 396.34 million and EPS of USD 0.07. Adjusted EBITDA was USD 21 million, full-year guidance was raised at the low end to USD 90 million, and the filing includes a going concern disclosure.